Approved Drugs for Cardiology/Vascular Diseases
Adcirca (tadalafil); Eli Lilly;
For the treatment of pulmonary arterial hypertension, Approved May 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Efient (prasugrel); Eli Lilly;
for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009
Livalo (pitavastatin); Kowa Company;
For the treatment of primary hyperlipidemia and mixed dyslipidemia, Approved August 2009
Multaq (dronedarone); Sanofi-aventis;
For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, Approved July 2009
Tyvaso (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension, Approved July 2009
Cleviprex (clevidipine); The Medicines Company;
For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008
Trilipix (fenofibric acid); Abbott Laboratories;
For the treatment of dyslipidemia, hypertriglyceridemia and hyperlipidemia, Approved December 2008
Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo;
For the treatment of hypertension, Approved September 2007
Fenofibrate; LifeCycle Pharma;
For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007
Letairis (ambrisentan); Gilead;
For the treatment of pulmonary arterial hypertension, Approved June 2007
Soliris (eculizumab); Alexion Pharm;
For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007
Tekturna (aliskiren); Novartis;
For the treatment of hypertension, Approved March 2007
Ranexa (ranolazine); CV Therapeutics;
For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006
BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed;
For the treatment of heart failure in black patients, Approved June, 2005
Caduet (amlodipine/atorvastatin ); Pfizer;
For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004
Crestor (rosuvastatin calcium); AstraZeneca;
For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia, Approved August 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Altocor (lovastatin) Extended-Release Tablets; Andrx;
Oral tablets for the adjuctive treatment of hypercholesterolemia, Approved June 2002
Benicar; Daiichi Sankyo;
Oral tablet for the treatment of hypertension, Approved April 2002
Imagent (perflexane lipid microspheres); Alliance Pharmaceutical;
Ultrasound contrast agent for improved imaging of the heart, Approved June 2002
Inspra (eplerenone tablets); Pharmacia;
Oral tablets for the treatment of high blood pressure., Approved September 2002
Plavix (clopidogrel bisulfate); Sanofi-aventis;
For the treatment of acute coronary syndrome, Approved February 2002
Remodulin (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002
Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals;
For the treatment of cholesterol disorders, Approved December 2001
Diovan (valsartan); Novartis;
Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)
Natrecor (nesiritide); Scios;
For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001
Teveten (eprosartan mesylate plus hydrochlorothiazide); Unimed Pharmaceuticals;
Tablets for the treatment of hypertension, Approved November 2001
Tricor (fenofibrate); Abbott Laboratories;
For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia, Approved September 2001
Angiomax (bivalirudin); The Medicines Company;
For patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), Approved December 2000
Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham;
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000
Atacand (candesartan cilexetil); AstraZeneca;
For the treatment of hypertension, Approved September 2000
Betapace AF Tablet; Berlex Laboratories;
For treatment of the irregular heartbeats in patients with atrial fibrillation, Approved February 2000
Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
For the reduction of high blood pressure, Approved January 2000
Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company;
For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000
Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000
Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
For the treatment of hypertension, Approved November 2000
Nitrostat (nitroglycerin) Tablets; Parke-Davis;
For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000
Lescol (fluvastatin sodium) capsules, Rx; Novartis;
Treatment for the reduction of triglycerides, Approved June 1999
Mevacor (lovastatin) tablets; Merck;
Treatment for primary prevention of coronary heart disease, Approved March 1999
Niaspan; Kos Pharmaceuticals;
Niacin extended-release tablets, October 28, 1999
Agrylin (anagrelide HCL); Roberts Pharmaceutical;
Treatment for Thrombocythemia, Approved December 1998
Atacand (candesartan cilexetil); Astra Merck;
Treatment for hypertension, Approved June 1998
Atacand (candesartan cilexetil); Astra Merck;
Treatment for hypertension, Approved June 1998
CellCept; Roche;
Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998
Diovan HCT (valsartan); Novartis;
Treatment for hypertension, Approved March 1998
Integrilin; COR Therapeutics, Key Pharmaceuticals;
Injection of eptifibatide, Approved May 1998
Micardis (telmisartan); Boehringer Ingelheim;
Treatment for Hypertension, Approved November 1998
Rythmol; Knoll Pharmaceutical;
Treatment for paroxysmal atrial fibrillation, Approved January 1998
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for chronic stable angina, Approved February 1998
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for chronic stable angina, Approved February 1998
Tricor (fenofibrate); Abbott Laboratories;
Treatment for very high triglyceride levels, Approved February 1998
Viagra; Pfizer;
Treatment for impotence, Approved March 1998
Baycol (cerivastatin sodium); Bayer;
Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01
Captopril and hydrochlorotiazide; Mylan Laboratories;
Generic equivalent of Capozide, Approved (tentatively) May 20, 1997
Captopril and hydrochlorotiazide; Mylan Laboratories;
Treatment for hypertension, Approved May 1997
Cardizem (R) (Diltiazem HC1 for injection) Monvial (R); Hoechst Marion Roussel;
Delivery system for Monovial, Approved September 1997
Corlopam; Neurex;
Treatment for severe high blood pressure, Approved September 1997
Diovan (valsartan); Ciba Pharmaceuticals;
Treatment for hypertension, Approved January 1997
DynaCirc CR; Novartis;
Treatment for hypertension, Approved February 1997
EDEX; Schwarz Pharma;
Treatment for erectile dysfunction, Approved June 1997
Lescol (fluvastatin sodium); Novartis;
Treatment for coronary atherosclerosis, Approved September 1997
Lexxel (enalapril maleate-felodipine ER); Astra Merck;
Treatment for hypertension, Approved January 1997
Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
Treatment for mild-to moderate hypertension, Approved January 1997
Normiflo; Wyeth;
Treatment for deep venous thrombosis, Approved May 1997
Pentoxifylline; Faulding, Mylan Laboratories;
Generic equivalent of Trental, Approved July 1997
Pindolol; Teva Pharmaceutical;
Generic equivalent of Visken, Approved April 1997
Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
Treatment for cardiac atherosclerotic events, Approved November 1997
Posicor; Roche;
Treatment for hypertension and chronic stable angina pectoris, Approved June 1997
ReoPro; Centocor;
Treatment for cardiac ischemic complications, Approved November 1997
REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
Generic equivalent of Pergonal, Approved February 1997
Teveten (eprosartan mesylate); SmithKline Beecham;
Treatment for hypertension, Approved December 1997
Verapamil; IVAX;
Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997
Warfarin Sodium tablets; Barr Laboratories;
Generic equivalent of Coumadin, Approved March 1997
Zocor; Merck;
Treatment for high cholesterol, Approved November 1997
Covera-HS (verapamil); G.D. Searle, Alza;
Treatment for hypertension and angina, Approved January 1996
Mavik (trandolapril); Knoll Pharmaceutical;
Treatment for hypertension, Approved May 1996
Muse; Vivus;
Treatment for impotence, Approved October 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for cholesterol-lowering, Approved July 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for heart disease, Approved April 1996
ProAmatine (midodrine); Roberts Pharmaceutical;
Treatment for hypotension, Approved September 1996
Procanbid (procainamide hydrochloride extended-release tablets); Warner-Lambert;
Treatment for ventricular arrhythmias, Approved January 1996
Retavase (reteplase); Boehringer Mannheim Corporation;
Treatment for patients suffering from heart attack, Approved November 1996
Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
Treatment for hypertension, Approved October 1996
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for hypertension, Approved February 1996
Visipaque (iodixanol); Nycomed;
Diagnostic contrast agent, Approved April 1996
Androderm (Testosterone Transdermal System); TheraTech;
Treatment for primary and secondary hypogonadism, Approved on September 29, 1995
Corvert Injection (ibutilide fumarate injection); Pharmacia & Upjohn;
Treatment for irregular contractions of the heart, Approved December 1995
Prinivil or Zestril (Lisinopril); Merck, Zeneca;
Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995
Toprol-XL (metoprolol succinate); AstraZeneca;
For the treatment of hypertension, angina pectoris and heart failure, Approved January 1995
